U.S., Dec. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07306624) titled 'Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer' on Dec. 14.
Brief Summary: A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy
Study Start Date: Jan. 10, 2026
Study Type: INTERVENTIONAL
Condition:
Non Small Cell Lung Cancer
Intervention:
DRUG: Nelmastobart and Docetaxel
Nelmastobart 800mg and Docetaxel 75mg/m2
Recruitment Status: RECRUITING
Sponsor: STCube, I...